Vicore Pharma Holding AB (STO:VICO), a Sweden-based clinical-stage pharmaceutical company, announced on Thursday the commencement of a first-in-human trial with the novel ATRAG C106.
Vicore expects this trial to read out during the third quarter of 2023.
The product is first of the four advanced candidate drugs from the VP03 programme to enter clinical trials. It is orally available with target engagement and anti-fibrotic impact in human fibrotic lung and kidney tissue at clinically relevant concentrations. It is likely to have patent protection until around 2040.
This first-in-human trial is a double-blind, placebo-controlled, randomised, single-centre trial to assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of the product. The trial is likely to include around 72 healthy volunteers and will be conducted in Uppsala, Sweden.
Genmab announces expansion of collaboration with BioNTech
Rheonix Opens New Laboratory Offering a Low-Cost COVID-19 PCR Testing Programme
Biomica doses first patient in BMC128 phase one clinical trial
Enhertu Granted Priority Review in the US for Patients with HER2 Low Metastatic Breast Cancer
GenFleet Therapeutics' GFH018 clinical trial applications receive Chinese regulatory approval